TAMI-52. G-CSF SECRETED BY EPIGENETICALLY REPROGRAMMED MUTANT IDH1 GLIOMA STEM CELLS, REVERSES THE MYELOID CELLS’-MEDIATED IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT

Mutation in isocitrate dehydrogenase (mIDH) is the main genetic lesion that defines clinical glioma subtypes and prognosis. This gain of function mutation is associated with the production of the oncometabolite, R-2-hydroxyglutarate, that inhibits α-ketoglutarate dependent enzymes such as TET2 and t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Alghamri, Mahmoud, Avvari, Ruthvik, Thalla, Rohit, Zhang, Li, Ventosa, Maria, Taher, Ayman, Núñez, Felipe, Heth, Jason, Orringer, Daniel, Lowenstein, Pedro, Castro, Maria
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Tumor Microenvironment/Angiogenesis/Metabolism/Invasion
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651463/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.939
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires